The 2015 Calendar Of NASH Trial Catalysts III: Galmed And Intercept
Clinically Sound Investor - at Seeking Alpha - Fri Dec 19, 11:23AM CST
GLMD: 5.95 (+0.15), ICPT: 151.49 (+5.85)
Critical Alerts For GoPro, Aeropostale, Magna International, Cliffs Natural Resources and Intercept Pharmaceuticals Released By InvestorsObserver
PR Newswire - Thu Dec 18, 8:31AM CST
InvestorsObserver issues critical PriceWatch Alerts for GPRO, ARO, MGA, CLF and ICPT.
GPRO: 66.41 (+4.87), ICPT: 151.49 (+5.85), MGA: 107.93 (+0.35), CLF: 6.06 (-0.09), ARO: 2.30 (-0.03)
Liver Fibrosis - Pipeline Review, H1 2014
M2 - Thu Dec 18, 4:04AM CST
Research and Markets (http://www.researchandmarkets.com/research/wmnbdp/liver_fibrosis) has announced the addition of the "Liver Fibrosis - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Liver Fibrosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Liver Fibrosis and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Liver Fibrosis - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Liver Fibrosis pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - Genzyme - Gilead Sciences - Bioneer - FibroGen - Silence Therapeutics - Celgene - Nitto Denko - Genfit - Pharmaxis - La Jolla Pharmaceutical - ProMetic Life Sciences - LG Life Sciences - Digna Biotech - Advinus Therapeutics - Promedior - GenKyoTex - Angion Biomedica - Virobay - Intercept Pharmaceuticals - Tobira Therapeutics - GNI Group - Promethera Biosciences - BiOrion Technologies - ACROVIS biostructures - RXi Pharmaceuticals For more information visit http://www.researchandmarkets.com/research/wm...r_fibrosis
GILD: 91.29 (+1.84), ICPT: 151.49 (+5.85), TBRA: (), CELGZ: 3.34 (-0.01)
Insider Trading Alert - ICPT, BOFI And JGW Traded By Insiders
at The Street - Tue Dec 16, 2:07PM CST
Stocks with insider trader activity include ICPT, BOFI and JGW
BOFI: 79.32 (+0.32), ICPT: 151.49 (+5.85), JGW: 10.70 (+0.04)
Twitter's Favorite Biotech and Pharma Stocks
Brian Orelli, The Motley Fool - Motley Fool - Tue Dec 16, 8:21AM CST
Mark Schoenebaum, the biotech and pharmaceutical analyst at Evercore ISI, asked the Twittersphere for their favorite drug stocks going into next year. What's your favorite stock for 2015 in biotech or Pharma? — Mark Schoenebaum...
BLUE: 88.76 (+3.23), BMRN: 88.18 (+0.89), TGTX: 16.03 (+0.33), BMY: 59.15 (-0.01), MACK: 10.91 (+0.36), FMI: 23.99 (-0.10), RNA: 18.76 (+0.10), GWPH: 68.08 (+1.82), SRPT: 13.88 (+0.47), MRK: 57.46 (+0.25), NLNK: 39.08 (+1.36), ICPT: 151.49 (+5.85), THLD: 2.93 (+0.01), CEMP: 20.66 (+0.78), NVS: 93.91 (+0.66)
Nasdaq makes annual changes to Biotechnology Index
Seeking Alpha - at Seeking Alpha - Mon Dec 15, 11:36AM CST
TTPH: 38.86 (+0.53), ZSPH: 43.93 (+1.77), AMRN: 0.99 (unch), OPHT: 44.93 (+1.06), AERI: 29.49 (+1.23), ASPX: 49.93 (-0.10), CNCE: 11.76 (+0.11), ICEL: 5.74 (-0.18), GWPH: 68.08 (+1.82), AUXL: 34.40 (+0.18), RTRX: 12.92 (+0.19), RCPT: 122.05 (+4.05), AAVL: 47.30 (-1.20), AKBA: 11.23 (-0.31), EXPR: 14.96 (+0.32), RARE: 45.17 (-0.56), RLYP: 30.35 (-0.22), PETX: 17.05 (+0.42), ENTA: 49.04 (+0.06), RDUS: 37.17 (+0.11), CARA: 9.78 (+0.02), FLML: 17.01 (-0.98), ALIM: 5.43 (-0.06), ANIP: 55.24 (+1.79), ICPT: 151.49 (+5.85), RVNC: 16.65 (+0.42), POZN: 7.86 (+0.07), FPRX: 26.12 (+0.07), ZFGN: 30.99 (+0.67), CRIS: 1.29 (+0.04), QLTI: 3.72 (+0.08), PCYC: 121.84 (+1.15), PTX: 9.05 (+0.28), CLDN: 18.54 (+0.85), RIGL: 2.22 (+0.02), HPTX: 21.91 (-0.08), AMPH: 11.74 (-0.09), INO: 9.11 (-0.09), VSAR: 22.25 (-0.11), FMI: 23.99 (-0.10), TBPH: 14.84 (+0.20), XLRN: 38.80 (+0.80), MGNX: 33.00 (+0.34), INSM: 15.29 (+0.15), ONTX: 3.82 (+0.06), ALDR: 25.67 (+0.43), SAGE: 38.13 (-0.75), KITE: 51.96 (+0.45), CGEN: 8.58 (-0.17), FOLD: 7.94 (+0.06), KPTI: 37.78 (+1.28)
Annual Changes to the NASDAQ Biotechnology Index
GlobeNewswire - Mon Dec 15, 6:10AM CST
The NASDAQ OMX Group, Inc. (Nasdaq:NDAQ) today announced the results of the annual re-ranking of the NASDAQ Biotechnology Index (Nasdaq:NBI), which will become effective prior to market open on Monday, December 22, 2014.
TTPH: 38.86 (+0.53), ZSPH: 43.93 (+1.77), AMRN: 0.99 (unch), OPHT: 44.93 (+1.06), AERI: 29.49 (+1.23), ASPX: 49.93 (-0.10), CNCE: 11.76 (+0.11), ICEL: 5.74 (-0.18), GWPH: 68.08 (+1.82), AUXL: 34.40 (+0.18), RTRX: 12.92 (+0.19), RCPT: 122.05 (+4.05), AAVL: 47.30 (-1.20), AKBA: 11.23 (-0.31), EXPR: 14.96 (+0.32), RARE: 45.17 (-0.56), ZGNX: 1.20 (+0.04), RLYP: 30.35 (-0.22), PETX: 17.05 (+0.42), ENTA: 49.04 (+0.06), RDUS: 37.17 (+0.11), CARA: 9.78 (+0.02), FLML: 17.01 (-0.98), ALIM: 5.43 (-0.06), ANIP: 55.24 (+1.79), ICPT: 151.49 (+5.85), RVNC: 16.65 (+0.42), POZN: 7.86 (+0.07), NDAQ: 48.74 (-0.40), FPRX: 26.12 (+0.07), CRIS: 1.29 (+0.04), ZFGN: 30.99 (+0.67), QLTI: 3.72 (+0.08), PCYC: 121.84 (+1.15), PTX: 9.05 (+0.28), CLDN: 18.54 (+0.85), RIGL: 2.22 (+0.02), HPTX: 21.91 (-0.08), AMPH: 11.74 (-0.09), INO: 9.11 (-0.09), VSAR: 22.25 (-0.11), FMI: 23.99 (-0.10), TBPH: 14.84 (+0.20), XLRN: 38.80 (+0.80), MGNX: 33.00 (+0.34), INSM: 15.29 (+0.15), ONTX: 3.82 (+0.06), ALDR: 25.67 (+0.43), SAGE: 38.13 (-0.75), KITE: 51.96 (+0.45), CGEN: 8.58 (-0.17), FOLD: 7.94 (+0.06), KPTI: 37.78 (+1.28)
Intercept Announces Publication of Meta-Analysis From the Global PBC Study Group in Gastroenterology
GlobeNewswire - Fri Dec 05, 5:25AM CST
- Largest Analysis of Data from Patients with Primary Biliary Cirrhosis
ICPT: 151.49 (+5.85)
How to Make Money in Biotech Stocks
Diana Gordon - Daily Reckoning - Wed Dec 03, 4:25PM CST
This post How to Make Money in Biotech Stocks appeared first on Daily Reckoning . Biotech stocks delivered triple-digit returns throughout the ’80s and ’90s. But it’s been a decade since we’ve seen similar results. Investment director Paul...
ICPT: 151.49 (+5.85), PBYI: 189.96 (+0.12)
Why Intercept Pharmaceuticals Inc. Stock Was Throttled in November
Sean Williams, The Motley Fool - Motley Fool - Mon Dec 01, 3:37PM CST
ICPT data by YCharts What: Shares of Intercept Pharmaceuticals , a clinical-stage biopharmaceutical company aiming to develop drugs to treat chronic liver disease, were absolutely throttled in November, losing 44% of their value based on...
ICPT: 151.49 (+5.85)
3 Biotech Stocks With Jaw-Dropping Growth Potential in 2015
George Budwell, The Motley Fool - Motley Fool - Sat Nov 29, 1:01PM CST
The biotech industry has been absolutely soaring over the past two years, fueled by a rise in drug approvals, an merger-and-acquisition frenzy, and widespread reorganizations that have helped to mitigate the impact of the so-called "patent cliff."...
JNJ: 104.59 (+0.31), FLML: 17.01 (-0.98), GERN: 3.06 (+0.05), ICPT: 151.49 (+5.85), IBB: 299.80 (+5.12)
Why Intercept Pharmaceuticals (ICPT) Could Be Positioned for a Slump - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Nov 25, 7:40AM CST
Intercept Pharmaceuticals has witnessed a significant price decline in the past four weeks and negative earnings estimate revisions for the current quarter and the current year, making it time for investors to sell it off
HSKA: 18.13 (+0.24), ICPT: 151.49 (+5.85), AMAG: 43.02 (+0.90), DYAX: 14.13 (+0.30)
Intercept to Present at Upcoming Investor Conferences
GlobeNewswire - Tue Nov 25, 5:04AM CST
Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT) (Intercept), a clinical stage biopharmaceutical company focused on the development and commercialization of novel bile acid therapeutics to treat chronic liver and intestinal diseases, today announced management will be participating in the following upcoming investor conferences:
ICPT: 151.49 (+5.85), DB: 30.95 (+0.04)
Tracking Ole Andreas Halvorsen's Viking Global Portfolio - Q3 2014 Update
John Vincent - at Seeking Alpha - Tue Nov 25, 2:06AM CST
CXO: 99.86 (-0.04), CAM: 50.11 (-0.19), MDLZ: 37.63 (+0.05), MON: 120.97 (-1.70), DAL: 48.05 (+0.92), KSU: 122.50 (-0.80), CFX: 52.40 (-0.35), KORS: 75.30 (-0.01), RL: 184.35 (+0.70), PCP: 241.29 (+0.29), GOOG: 528.77 (-1.82), MOH: 53.39 (+0.61), PBR: 7.60 (-0.11), HLT: 26.21 (+0.11), DLTR: 69.86 (-0.20), LYB: 81.31 (-0.89), COF: 83.23 (-0.05), FOXA: 38.71 (-0.03), ABBV: 66.21 (+1.86), LOW: 67.51 (-0.43), REGN: 400.12 (+6.07), MA: 87.77 (+0.14), MU: 34.91 (-0.06), FB: 80.77 (+0.16), LNG: 71.64 (-0.12), NFX: 27.86 (-0.39), PXD: 150.84 (-1.60), ALXN: 181.96 (+3.09), ICPT: 151.49 (+5.85), CTSH: 54.26 (+0.04), ADSK: 60.99 (+0.34), DHI: 24.80 (-0.01), CCI: 79.05 (-0.13), ACT: 254.20 (-1.68), LBTYK: 49.10 (+0.05), MDT: 74.08 (+0.31), C: 54.54 (+0.12), ILMN: 186.22 (+2.72), AON: 96.52 (-0.15), ADBE: 74.74 (+0.36), MMC: 58.32 (-0.07), HUM: 144.38 (-0.31), AGN: 210.12 (+0.95), ACAD: 30.95 (+0.78), LBTYA: 50.76 (-0.02), GOOGL: 536.93 (-1.84), AAPL: 112.01 (-0.53), APD: 148.58 (unch), HRB: 33.72 (-0.08), GLNG: 36.67 (+1.15), BAC: 17.98 (+0.05), NFLX: 342.10 (+5.67), HCA: 74.89 (-0.11), BIDU: 230.98 (-2.18), DVA: 76.06 (+0.07), KITE: 51.96 (+0.45), MHK: 154.56 (-0.21), CP: 194.85 (-0.13), BABA: 105.95 (+0.43)
Critical Alerts For JA Solar, 2U, AT&T, Mobileye NV and Intercept Pharmaceuticals Released By InvestorsObserver
PR Newswire - Wed Nov 19, 8:31AM CST
InvestorsObserver issues critical PriceWatch Alerts for JASO, TWOU, T, MBLY and ICPT.
T: 33.96 (-0.07), JASO: 8.03 (+0.13), ICPT: 151.49 (+5.85), TWOU: 19.44 (-0.18), MBLY: 44.00 (+0.05)
Pharma Industry Outlook: M&A, Licensing Abound - Industry Outlook
Arpita Dutt - Zacks Investment Research - Wed Nov 19, 12:00AM CST
Pharma Industry Outlook: M&A, Licensing Abound - Industry Outlook
ACT: 254.20 (-1.68), QLTI: 3.72 (+0.08), VRX: 140.33 (-0.22), AGN: 210.12 (+0.95), SHPG: 209.29 (+0.07), AUXL: 34.40 (+0.18), ABBV: 66.21 (+1.86), SNY: 46.35 (+0.50), ABT: 45.70 (-0.02), ENDP: 72.10 (+0.34), AKRX: 36.47 (+0.43), PFE: 31.42 (-0.03), INCY: 71.57 (+1.99), SLXP: 114.92 (-1.18), MYL: 56.97 (+0.39), AMGN: 160.67 (+3.15), LLY: 70.16 (+0.42), GSK: 42.85 (+0.11), BMY: 59.15 (-0.01), ACHN: 13.06 (+1.22), MRK: 57.46 (+0.25), AZN: 70.44 (+0.26), ICPT: 151.49 (+5.85), TEVA: 57.09 (+0.33), NVS: 93.91 (+0.66)
Pharma Industry Outlook: M&A, Licensing Abound - Zacks Analyst Interviews
Arpita Dutt - Zacks Investment Research - Wed Nov 19, 12:00AM CST
Pharma Industry Outlook: M&A, Licensing Abound - Zacks Analyst Interviews
ACT: 254.20 (-1.68), QLTI: 3.72 (+0.08), VRX: 140.33 (-0.22), AGN: 210.12 (+0.95), SHPG: 209.29 (+0.07), AUXL: 34.40 (+0.18), ABBV: 66.21 (+1.86), SNY: 46.35 (+0.50), ABT: 45.70 (-0.02), ENDP: 72.10 (+0.34), AKRX: 36.47 (+0.43), PFE: 31.42 (-0.03), INCY: 71.57 (+1.99), SLXP: 114.92 (-1.18), MYL: 56.97 (+0.39), AMGN: 160.67 (+3.15), LLY: 70.16 (+0.42), GSK: 42.85 (+0.11), BMY: 59.15 (-0.01), ACHN: 13.06 (+1.22), MRK: 57.46 (+0.25), AZN: 70.44 (+0.26), ICPT: 151.49 (+5.85), TEVA: 57.09 (+0.33), NVS: 93.91 (+0.66)
Intercept Pharmaceuticals hires Lisa Bright as head of Europe
M2 - Tue Nov 18, 6:30AM CST
Biopharmaceutical company Intercept Pharmaceuticals (NasdaqGS:ICPT) revealed on Monday the election of Lisa Bright as senior vice president and head of Europe.
ICPT: 151.49 (+5.85)
Intercept Pharmaceuticals names Lisa Bright as senior vice president and head of Europe
M2 - Mon Nov 17, 6:48AM CST
Biopharmaceutical company Intercept Pharmaceuticals (NasdaqGS:ICPT) has appointed Lisa Bright as senior vice president and head of Europe, it revealed on Friday.
ICPT: 151.49 (+5.85)
Intercept Pharmaceuticals Appoints Lisa Bright as Head of Europe
GlobeNewswire - Mon Nov 17, 5:01AM CST
Intercept Pharmaceuticals (Nasdaq:ICPT), a clinical stage biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat chronic liver and intestinal diseases, announced today the appointment of Lisa Bright as Senior Vice President and Head of Europe, effective November 17, 2014. Ms. Bright will be a member of the Intercept senior management team and will spearhead Intercept's European operations based in London as the company prepares for the first indication approval and launch of obeticholic acid (OCA).
GILD: 91.29 (+1.84), ICPT: 151.49 (+5.85)